Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α
Identifieur interne : 000080 ( Istex/Corpus ); précédent : 000079; suivant : 000081Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α
Auteurs : Ute Ströher ; Antonino Dicaro ; Yan Li ; James E. Strong ; Fred Aoki ; Frank Plummer ; Steven M. Jones ; Heinz FeldmannSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 2004.
Abstract
Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.
Url:
DOI: 10.1086/382597
Links to Exploration step
ISTEX:FF63A99965ECDC1E7144CBE4D3273B2F908720A3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title><author><name sortKey="Stroher, Ute" sort="Stroher, Ute" uniqKey="Stroher U" first="Ute" last="Ströher">Ute Ströher</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Dicaro, Antonino" sort="Dicaro, Antonino" uniqKey="Dicaro A" first="Antonino" last="Dicaro">Antonino Dicaro</name><affiliation><mods:affiliation>Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Strong, James E" sort="Strong, James E" uniqKey="Strong J" first="James E." last="Strong">James E. Strong</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Plummer, Frank" sort="Plummer, Frank" uniqKey="Plummer F" first="Frank" last="Plummer">Frank Plummer</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jones, Steven M" sort="Jones, Steven M" uniqKey="Jones S" first="Steven M." last="Jones">Steven M. Jones</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Immunology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: heinz_feldmann@hc-sc.gc.ca</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Heinz Feldmann, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2 (heinz_feldmann@hc-sc.gc.ca).</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FF63A99965ECDC1E7144CBE4D3273B2F908720A3</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1086/382597</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000080</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000080</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title><author><name sortKey="Stroher, Ute" sort="Stroher, Ute" uniqKey="Stroher U" first="Ute" last="Ströher">Ute Ströher</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Dicaro, Antonino" sort="Dicaro, Antonino" uniqKey="Dicaro A" first="Antonino" last="Dicaro">Antonino Dicaro</name><affiliation><mods:affiliation>Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Strong, James E" sort="Strong, James E" uniqKey="Strong J" first="James E." last="Strong">James E. Strong</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Plummer, Frank" sort="Plummer, Frank" uniqKey="Plummer F" first="Frank" last="Plummer">Frank Plummer</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jones, Steven M" sort="Jones, Steven M" uniqKey="Jones S" first="Steven M." last="Jones">Steven M. Jones</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Immunology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name><affiliation><mods:affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: heinz_feldmann@hc-sc.gc.ca</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Heinz Feldmann, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2 (heinz_feldmann@hc-sc.gc.ca).</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">2004</date><biblScope unit="vol">189</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1164">1164</biblScope><biblScope unit="page" to="1167">1167</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>sars</json:string><json:string>ribavirin</json:string><json:string>viral</json:string><json:string>antiviral</json:string><json:string>interferon</json:string><json:string>coronavirus</json:string><json:string>dmem</json:string><json:string>severe acute respiratory syndrome</json:string><json:string>inhibitory effect</json:string><json:string>vero</json:string><json:string>cell monolayers</json:string><json:string>immunoblot analysis</json:string><json:string>replication</json:string><json:string>datum</json:string><json:string>limited number</json:string><json:string>brief report</json:string><json:string>present study</json:string><json:string>cell lysates</json:string><json:string>syndrome</json:string><json:string>tissue culture</json:string><json:string>various amount</json:string><json:string>viral antigen</json:string><json:string>patient serum sample</json:string><json:string>clinical trial</json:string><json:string>human serum</json:string><json:string>cell culture</json:string><json:string>antiviral effect</json:string><json:string>concentration attainable</json:string><json:string>mouse hepatitis virus</json:string><json:string>porcine transmissible gastroenteritis virus</json:string><json:string>toronto patient</json:string><json:string>virus growth</json:string><json:string>viral protein expression</json:string><json:string>serum sample</json:string><json:string>plaque assay</json:string><json:string>antiviral activity</json:string><json:string>cytopathic effect</json:string><json:string>serum concentration</json:string><json:string>cynomolgus macaque</json:string><json:string>hong kong</json:string><json:string>sars virus</json:string></teeft></keywords><author><json:item><name>Ute Ströher</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string><json:string>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Antonino DiCaro</name><affiliations><json:string>Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS, Rome, Italy</json:string></affiliations></json:item><json:item><name>Yan Li</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string><json:string>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>James E. Strong</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Fred Aoki</name><affiliations><json:string>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Frank Plummer</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string><json:string>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Steven M. Jones</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string><json:string>Department of Immunology, University of Manitoba, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Heinz Feldmann</name><affiliations><json:string>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</json:string><json:string>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</json:string><json:string>E-mail: heinz_feldmann@hc-sc.gc.ca</json:string><json:string>Reprints or correspondence: Dr. Heinz Feldmann, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2 (heinz_feldmann@hc-sc.gc.ca).</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-KP6RTLL1-8</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>brief-report</json:string></originalGenre><abstract>Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.</abstract><qualityIndicators><score>4.413</score><pdfWordCount>2498</pdfWordCount><pdfCharCount>15270</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><pdfWordsPerPage>625</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>104</abstractWordCount><abstractCharCount>727</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title><pmid><json:string>15031783</json:string></pmid><genre><json:string>brief-communication</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>189</volume><issue>7</issue><pages><first>1164</first><last>1167</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>5000</json:string><json:string>1000</json:string><json:string>2004</json:string></date><geogName></geogName><orgName><json:string>University of Manitoba</json:string><json:string>Istituto Nazionale</json:string><json:string>Italy Current</json:string><json:string>Severe Acute Respiratory Syndrome Task Force</json:string></orgName><orgName_funder><json:string>Severe Acute Respiratory Syndrome Task Force</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Asia Paci</json:string><json:string>L. Spallanzani</json:string><json:string>Fred Aoki</json:string><json:string>Heinz Feldmann</json:string><json:string>Yan Li</json:string><json:string>Steven M. Jones</json:string><json:string>Frank Plummer</json:string></persName><placeName><json:string>Winnipeg</json:string><json:string>Canada</json:string><json:string>China</json:string><json:string>Toronto</json:string><json:string>America</json:string><json:string>Rome</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[18]</json:string><json:string>[6]</json:string><json:string>[8]</json:string><json:string>[17]</json:string><json:string>[9, 10]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-KP6RTLL1-8</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1086/382597</json:string></doi><id>FF63A99965ECDC1E7144CBE4D3273B2F908720A3</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 2004 by the Infectious Diseases Society of America</licence></availability><date type="Copyright" when="2004">2004</date><date type="published">2004</date></publicationStmt><notesStmt><note type="content-type" source="brief-report" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="brief-report"><analytic><title level="a" type="main">Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title><author xml:id="author-0000"><persName><surname>Ströher</surname><forename type="first">Ute</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation><affiliation><orgName type="institution">Department of Medical Microbiology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0001"><persName><surname>DiCaro</surname><forename type="first">Antonino</forename></persName><affiliation><orgName type="institution">Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS</orgName><address><addrLine>Rome, Italy</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><surname>Li</surname><forename type="first">Yan</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation><affiliation><orgName type="institution">Department of Medical Microbiology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><surname>Strong</surname><forename type="first">James E.</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><surname>Aoki</surname><forename type="first">Fred</forename></persName><affiliation><orgName type="institution">Department of Medical Microbiology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><surname>Plummer</surname><forename type="first">Frank</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation><affiliation><orgName type="institution">Department of Medical Microbiology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><surname>Jones</surname><forename type="first">Steven M.</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation><affiliation><orgName type="institution">Department of Immunology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><author xml:id="author-0007" role="corresp"><persName><surname>Feldmann</surname><forename type="first">Heinz</forename></persName><affiliation><orgName type="institution">National Microbiology Laboratory, Health Canada</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation><affiliation><orgName type="institution">Department of Medical Microbiology, University of Manitoba</orgName><address><addrLine>Winnipeg, Canada</addrLine></address></affiliation></author><idno type="istex">FF63A99965ECDC1E7144CBE4D3273B2F908720A3</idno><idno type="ark">ark:/67375/HXZ-KP6RTLL1-8</idno><idno type="DOI">10.1086/382597</idno></analytic><monogr><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">2004</date><biblScope unit="vol">189</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1164">1164</biblScope><biblScope unit="page" to="1167">1167</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.41" when="2020-04-06"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Major Articles and Brief Reports</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2020-04-06" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="brief-report">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1086/382597</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Major Articles and Brief Reports</subject>
<subj-group subj-group-type="heading">
<subject>Viruses</subject>
<subj-group subj-group-type="heading">
<subject>Brief Reports</subject>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ströher</surname><given-names>Ute</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>DiCaro</surname><given-names>Antonino</given-names></name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Yan</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Strong</surname><given-names>James E.</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aoki</surname><given-names>Fred</given-names></name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Plummer</surname><given-names>Frank</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jones</surname><given-names>Steven M.</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Feldmann</surname><given-names>Heinz</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<aff id="aff1"><label>1</label><institution>National Microbiology Laboratory, Health Canada</institution>, <addr-line>Winnipeg, Canada</addr-line></aff>
<aff id="aff2"><label>2</label><institution>Department of Medical Microbiology, University of Manitoba</institution>, <addr-line>Winnipeg, Canada</addr-line></aff>
<aff id="aff3"><label>3</label><institution>Department of Immunology, University of Manitoba</institution>, <addr-line>Winnipeg, Canada</addr-line></aff>
<aff id="aff4"><label>4</label><institution>Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS</institution>, <addr-line>Rome, Italy</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Reprints or correspondence: Dr. Heinz Feldmann, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2 (<email>heinz_feldmann@hc-sc.gc.ca</email>).</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>4</month>
<year>2004</year>
</pub-date>
<volume>189</volume>
<issue>7</issue>
<fpage>1164</fpage>
<lpage>1167</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>7</month>
<year>2003</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>10</month>
<year>2003</year>
</date>
</history>
<copyright-statement>© 2004 by the Infectious Diseases Society of America</copyright-statement>
<copyright-year>2004</copyright-year>
<abstract>
<p>Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.</p>
</abstract>
</article-meta>
</front>
<body>
<p>As of 23 June 2003, the rapid worldwide dissemination of severe acute respiratory syndrome (SARS) has resulted in 30 countries reporting 8459 cases. The Asia Pacific region, including mainland China, has been most severely affected by the disease, but western countries, most notably Canada, also have reported cases. The global interest in the epidemic has pushed science forward, so that, within weeks of the outbreak being identified, the potential causative agent was isolated from several patients with SARS, and the full-length sequence was determined. Genetic analysis identified the agent as a newly emerged coronavirus (CoV) (order <italic>Nidovirales</italic>, family <italic>Coronaviridae</italic>, genus <italic>Coronavirus</italic>), which is different from all previously known groups of CoVs [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>].</p>
<p>Despite the early success in molecular characterization, progress has been less rapid in other areas, particularly in establishing an antiviral treatment for patients with SARS. SARS is primarily diagnosed by a process of clinical/epidemiological exclusion. Despite improvement in the recent past, laboratory diagnosis, particularly molecular detection of the virus by polymerase chain reaction, remains unreliable, especially in the first few days of the disease; in addition, the tests are not yet validated. Serologic analysis is thought to be the confirmatory laboratory test, but most patients with SARS develop detectable IgG antibody levels 3-4 weeks after the onset of symptoms. Thus, differential diagnosis remains a problem for the clinician at the time of initial presentation, particularly in individuals without known exposure to other patients with SARS or history of travel to a region where SARS is endemic.</p>
<p>The case-fatality rate of 9.5% reflects, in part, the lack of an effective specific treatment for this viral infection. Broad-spectrum antibiotics to treat community-acquired bacterial pneumonia, glucocorticoids, and ribavirin have been administered to patients with SARS, but their efficacy is unknown [<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref>]. Recently, glycyrrhizin has been demonstrated to inhibit the SARS-related CoV (SARS CoV) in vitro [<xref ref-type="bibr" rid="R6">6</xref>]. Ribavirin has been used on the basis of its ability to inhibit other CoVs [<xref ref-type="bibr" rid="R7">7</xref>] and also showed an inhibitory effect on several other RNA viruses, such as bunyaviruses and arenaviruses [<xref ref-type="bibr" rid="R8">8</xref>]. To support the search for effective antiviral treatments, we evaluated the susceptibility of SARS CoV isolates (detailed studies were performed with the Tor2 isolate [Toronto, Canada]) to ribavirin and interferon (IFN)-α-2b in vitro. Our data indicate that ribavirin does not inhibit the virus at concentrations attainable in human serum but that IFN-α-2b may be useful and deserves further evaluation as a therapeutic agent.</p>
<p><italic><bold>Materials and methods.</bold></italic> Studies were performed with the recently sequenced Tor2 isolate, obtained from a Toronto patient [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R4">4</xref>]. The general findings were confirmed by use of 3 additional independently obtained isolates from Toronto patients (Tor3, Tor7, and Tor684). All isolates originated from nasopharyngeal swabs. Vero E6 cells (ATCC 1568) were used for the susceptibility studies. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Gibco BRL).</p>
<p>Vero E6 cells were infected at an MOI of 0.001 with the SARS CoV. After 1 h of adsorption, the supernatants were replaced with DMEM containing various amounts of ribavirin (0-2000 µg/mL) or IFN-α-2b (0-5000 IU/mL) (Schering-Plough) for 72 or 96 h.</p>
<p>For immunoblot analysis, cell lysates were analyzed by SDSPAGE on 10% Tris gels. Protein was electrotransferredtopolyvinylidene difluoride membrane (Immobilon P membrane; Millipore). Viral antigen was detected by use of enhanced chemiluminescence, using a patient serum sample and horseradish peroxidase-conjugated anti-human IgG.</p>
<p>For plaque assay, confluent Vero E6 cells were infected in 10-fold dilutions of SARS CoV; 45 min after infection, the inoculum was removed, and cell monolayers were overlaid with 0.9% lowmelting- point agarose inDMEM,with or without IFN-α-2b.Titers were determined 72 h after infection, following crystal violet staining.</p>
<p>For microassay, Vero E6 cells were infected with SARS CoV at an MOI of 0.001 for 45 min at 37°C and then were incubated in DMEM containing various amounts of IFN-α-2b (0-5000 IU/mL); 72 h after infection, cells were formalin fixed, removed from biocontainment, and analyzed by use of phase-contrast microscopy, using an Axiovert 200 microscope (Zeiss).</p>
<p><italic><bold>Results.</bold></italic> In vitro studies were conducted in Vero E6 cells, which is one of only a limited number of cell lines susceptible to SARS CoV. Vero E6 cell monolayers were treated with ribavirin at various concentrations (0, 20, 50, 100, 200, 1000, and 2000 µg/mL) for 96 h. Treatment was initiated concurrently with inoculation of the cell cultures with virus at an MOI of 0.001. Inhibition of viral cytopathic effect (CPE) was used to determine the antiviral effect of the drug. No reduction in CPE was detected after 4 days, compared with untreated control samples. Viral titers determined from tissue culture supernatant were identical for treated and untreated cells and amounted to ∼10<sup>6</sup> pfu/mL (data not shown). Ribavirin was tested up to concentrations 10 times greater (2000 µg/mL) than those that inhibit the replication of ribavirin-sensitive viruses, such as arenaviruses and bunyaviruses [<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>]. There was no evidence that the SARS CoV was susceptible to the action of ribavirin.</p>
<p>IFN susceptibility has been demonstrated for several coronaviruses, such as mouse hepatitis virus, porcine transmissible gastroenteritis virus, feline infectious peritonitis virus, and human coronavirus [<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R14">14</xref>]. Inhibitory concentrations ranged from 2 IU/mL [<xref ref-type="bibr" rid="R12">12</xref>] to 1000 IU/mL [<xref ref-type="bibr" rid="R14">14</xref>]. Therefore, we tested the susceptibility of the Tor2 isolate to IFN-α-2b (Schering- Plough). In brief, Vero E6 cells were infected at an MOI of 0.001, either 20 h after or at the time of treatment with IFN-α- 2b (250-5000 IU/mL). Treatment was continued for 72 h. The CPE was used to demonstrate an antiviral effect. As indicated in <xref ref-type="fig" rid="F1">figure 1</xref>, the CPE on day 3 after infection was significantly decreased in Tor2-infected cultures treated with 1000 IU/mL of IFN-α-2b in both treatment groups, compared with that in the untreated control group. This indicated that pretreatment was not necessary for the protective effect in tissue culture (data not shown). Almost complete protection was achieved when infected Vero E6 cells were treated with 5000 IU/mL of IFN-α-2b.</p>
<p>To quantify the effect of IFN-α-2b on the replication of the SARS CoV, Vero E6 cells were infected at an MOI of 0.001 and were incubated in the presence IFN-α-2b (0-5000 IU/mL), as described above. After 72 h, cells and supernatants were harvested to determine protein expression by immunoblot analysis and virus yield by plaque titration on Vero E6 cells. As indicated in <xref ref-type="fig" rid="F2">figure 2<italic>A</italic></xref>, a concentration of 1000 IU/mL of IFN-α-2b substantially reduced virus yields, and ∼1 log decrease in virus yield was achieved at a dose of 2000 IU/mL of IFN-α-2b. The reduction in virus yield seems to be related to a decrease in virus growth, as supported by the change in the plaque morphology (<xref ref-type="fig" rid="F2">figure 2<italic>B</italic></xref>). Inhibition of viral protein expression was investigated by use of immunoblot analysis after SDS-PAGE of the cell lysates (<xref ref-type="fig" rid="F2">figure 2<italic>C</italic></xref>). A serum sample from a patient with SARS who seroconverted to the SARS CoV was used to detect viral proteins. Earlier studies had shown that this serum sample reacted strongly with the nucleocapsid protein of the SARS CoV [<xref ref-type="bibr" rid="R15">15</xref>]. Viral protein expression was reduced at a concentration of 1000 IU/mL and abolished at concentrations of 2000 and 5000 IU/mL of IFN-α-2b.</p>
<p>For confirmation, the effect of IFN-α-2b on 3 additional independent SARS CoV isolates (Tor3, Tor7, and Tor684) obtained from Canadian patients with SARS was determined. All isolates showed the same pattern of inhibition by IFN-α-2b as the Tor2 isolate (<xref ref-type="fig" rid="F2">figure 2<italic>D</italic></xref>). For all isolates, the IC50 of IFN-α-2b was ∼500 IU/mL.</p>
<p><italic><bold>Discussion.</bold></italic> The present study has demonstrated that the SARS CoV is not susceptible to ribavirin at high concentrations, even when added at the time of infection. In contrast, the virus is inhibited in tissue culture by IFN-α-2b at concentrations ⩾1000 IU/mL. Although the relationship between in vitro and serum IFN concentrations and biological effect is not known, peak serum IFN concentrations of at least 500 IU/mL are observed after intramuscular (im) injection of 3.0×10<sup>7</sup> IU/mL [<xref ref-type="bibr" rid="R16">16</xref>]. Similar IFN serum concentrations (100-750 IU/mL) after im injection were reported from a study in patients with hepatitis C virus (HCV)-associated systemic vasculitis [<xref ref-type="bibr" rid="R17">17</xref>]. Doses up to 3.6×10<sup>7</sup> IU/mL have been infused intravenously, which might achieve serum concentrations in the range observed to inhibit the SARS CoV. At present, there is no data on the serum levels of IFN-α in patients with SARS, which would be helpful before treatment.</p>
<p>The in vitro studies have thus far only been performed in Vero E6 cells. This is significant, because Vero E6 cells have been shown to have an IFN I gene deficiency and thus are unable to express endogenous IFN I [<xref ref-type="bibr" rid="R18">18</xref>]. However, the IFNdependent pathways are functional and can be activated by exogenously provided IFN. We have tested a limited number of different cell lines (HeLa, 293T, 3T3, and CRFK) for susceptibility to the SARS CoV; thus far, we have failed to identify another line that supports viral replication (data not shown). The observation that the Vero cell clone E6 propagates the virus may indeed be related to the lack of a functional IFN system and, thus, supports the findings in the present study.</p>
<p>Despite efforts by our group and others to grow the virus in different rodent species, a small animal model has not yet been established. Recently, cynomolgus macaques (<italic>Macaca fascicularis</italic>) have been infected with the SARS CoV, which induced similar clinical symptoms and pathological findings to those of humans with SARS [<xref ref-type="bibr" rid="R19">19</xref>]. Because only a limited number of animals have been used in the present study, it remains to be determined in the future whether the cynomolgus macaque is a suitable model for SARS and, thus, for antiviral in vivo studies. Until an animal model is definitively established, it might be justified to consider clinical trials with IFN, which is already approved for human use, to determine whether IFN has a beneficial effect on the outcome of SARS CoV infection. Combined with the observation of a lack of efficacy of ribavirin in patients with SARS, our in vitro data further support the conclusion that ribavirin, at least alone, is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infection. Whether combined therapy with IFN-α-2b and ribavirin would inhibit the replication of the SARS CoV in vitro has not yet been evaluated; the combination is more effective than either agent used alone for the treatment of HCV infection in humans.</p>
</body>
<back>
<ack>
<title>Acknowledgement</title>
<p>We thank the Severe Acute Respiratory Syndrome Task Force at the Canadian Science Centre for Human and Animal Health for valuable discussions.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marra</surname><given-names>MA</given-names></name>
<name><surname>Jones</surname><given-names>SJ</given-names></name>
<name><surname>Astell</surname><given-names>CR</given-names></name>
<etal></etal>
</person-group>
<article-title>The genome sequence of the SARS-associated coronavirus</article-title>
<source>Science</source>
<year>2003</year>
<volume>300</volume>
<fpage>1399</fpage>
<lpage>404</lpage>
</nlm-citation>
</ref>
<ref id="R2">
<label>2.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rota</surname><given-names>PA</given-names></name>
<name><surname>Oberste</surname><given-names>MS</given-names></name>
<name><surname>Monroe</surname><given-names>SS</given-names></name>
<etal></etal>
</person-group>
<article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title>
<source>Science</source>
<year>2003</year>
<volume>300</volume>
<fpage>1394</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="R3">
<label>3.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>N</given-names></name>
<name><surname>Hui</surname><given-names>D</given-names></name>
<name><surname>Wu</surname><given-names>A</given-names></name>
<etal></etal>
</person-group>
<article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title>
<source>N Engl J Med</source>
<year>2003</year>
<volume>348</volume>
<fpage>1986</fpage>
<lpage>94</lpage>
</nlm-citation>
</ref>
<ref id="R4">
<label>4.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poutanen</surname><given-names>SM</given-names></name>
<name><surname>Low</surname><given-names>DE</given-names></name>
<name><surname>Henry</surname><given-names>B</given-names></name>
<etal></etal>
</person-group>
<article-title>Identification of severe acute respiratory syndrome in Canada</article-title>
<source>N Engl J Med</source>
<year>2003</year>
<volume>348</volume>
<fpage>1995</fpage>
<lpage>2005</lpage>
</nlm-citation>
</ref>
<ref id="R5">
<label>5.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsang</surname><given-names>KW</given-names></name>
<name><surname>Ho</surname><given-names>PL</given-names></name>
<name><surname>Ooi</surname><given-names>GC</given-names></name>
<etal></etal>
</person-group>
<article-title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</article-title>
<source>N Engl J Med</source>
<year>2003</year>
<volume>348</volume>
<fpage>1977</fpage>
<lpage>85</lpage>
</nlm-citation>
</ref>
<ref id="R6">
<label>6.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cinatl</surname><given-names>J</given-names></name>
<name><surname>Morgenstern</surname><given-names>B</given-names></name>
<name><surname>Bauer</surname><given-names>G</given-names></name>
<name><surname>Chandra</surname><given-names>P</given-names></name>
<name><surname>Rabenau</surname><given-names>H</given-names></name>
<name><surname>Doerr</surname><given-names>HW</given-names></name>
</person-group>
<article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>361</volume>
<fpage>2045</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="R7">
<label>7.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>RC</given-names></name>
<name><surname>Oostrom-Ram</surname><given-names>T</given-names></name>
</person-group>
<article-title>Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro</article-title>
<source>Vet Microbiol</source>
<year>1989</year>
<volume>20</volume>
<fpage>255</fpage>
<lpage>65</lpage>
</nlm-citation>
</ref>
<ref id="R8">
<label>8.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huggins</surname><given-names>JW</given-names></name>
</person-group>
<article-title>Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug</article-title>
<source>Rev Infect Dis</source>
<year>1989</year>
<volume>11</volume>
<issue>(Suppl 4)</issue>
<fpage>S750</fpage>
<lpage>61</lpage>
</nlm-citation>
</ref>
<ref id="R9">
<label>9.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berezina</surname><given-names>LK</given-names></name>
<name><surname>Leont'eva</surname><given-names>NA</given-names></name>
<name><surname>Kondrashina</surname><given-names>NG</given-names></name>
<name><surname>L'Vov</surname><given-names>DK</given-names></name>
<name><surname>Gagelov</surname><given-names>GA</given-names></name>
</person-group>
<article-title>Effect of ribavirin on bunyavirus reproduction in cell culture and in an experiment on white mice</article-title>
<source>Vopr Virusol</source>
<year>1983</year>
<volume>28</volume>
<fpage>627</fpage>
<lpage>9</lpage>
<comment>[in Russian]</comment>
</nlm-citation>
</ref>
<ref id="R10">
<label>10.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrei</surname><given-names>G</given-names></name>
<name><surname>De Clercq</surname><given-names>E</given-names></name>
</person-group>
<article-title>Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro</article-title>
<source>Antiviral Res</source>
<year>1990</year>
<volume>14</volume>
<fpage>287</fpage>
<lpage>99</lpage>
</nlm-citation>
</ref>
<ref id="R11">
<label>11.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garlinghouse</surname><given-names>LE</given-names><suffix>Jr.</suffix></name>
<name><surname>Smith</surname><given-names>AL</given-names></name>
<name><surname>Holford</surname><given-names>T</given-names></name>
</person-group>
<article-title>The biological relationship of mouse hepatitis virus (MHV) strains and interferon: in vitro induction and sensitivities</article-title>
<source>Arch Virol</source>
<year>1984</year>
<volume>82</volume>
<fpage>19</fpage>
<lpage>29</lpage>
</nlm-citation>
</ref>
<ref id="R12">
<label>12.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sperber</surname><given-names>SJ</given-names></name>
<name><surname>Hayden</surname><given-names>FG</given-names></name>
</person-group>
<article-title>Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta</article-title>
<source>J Interferon Res</source>
<year>1989</year>
<volume>9</volume>
<fpage>285</fpage>
<lpage>93</lpage>
</nlm-citation>
</ref>
<ref id="R13">
<label>13.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mochizuki</surname><given-names>M</given-names></name>
<name><surname>Nakatani</surname><given-names>H</given-names></name>
<name><surname>Yoshida</surname><given-names>M</given-names></name>
</person-group>
<article-title>Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro</article-title>
<source>Vet Microbiol</source>
<year>1994</year>
<volume>39</volume>
<fpage>145</fpage>
<lpage>52</lpage>
</nlm-citation>
</ref>
<ref id="R14">
<label>14.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>LT</given-names></name>
<name><surname>Derbyshire</surname><given-names>JB</given-names></name>
</person-group>
<article-title>Antiviral action of interferon-alpha against porcine transmissible gastroenteritis virus</article-title>
<source>Vet Microbiol</source>
<year>1995</year>
<volume>45</volume>
<fpage>59</fpage>
<lpage>70</lpage>
</nlm-citation>
</ref>
<ref id="R15">
<label>15.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krokhin</surname><given-names>O</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Andonov</surname><given-names>A</given-names></name>
<etal></etal>
</person-group>
<article-title>Mass spectrometric characterization of proteins from the SARS virus: a preliminary report</article-title>
<source>Mol Cell Proteomics</source>
<year>2003</year>
<volume>2</volume>
<fpage>346</fpage>
<lpage>56</lpage>
</nlm-citation>
</ref>
<ref id="R16">
<label>16.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wills</surname><given-names>RJ</given-names></name>
</person-group>
<article-title>Clinical pharmacokinetics of interferons</article-title>
<source>Clin Pharmacokinet</source>
<year>1990</year>
<volume>19</volume>
<fpage>390</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="R17">
<label>17.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hausfater</surname><given-names>P</given-names></name>
<name><surname>Cacoub</surname><given-names>P</given-names></name>
<name><surname>Assogba</surname><given-names>U</given-names></name>
<name><surname>Lebon</surname><given-names>P</given-names></name>
<name><surname>Piette</surname><given-names>JC</given-names></name>
</person-group>
<article-title>Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis</article-title>
<source>Nephron</source>
<year>2002</year>
<volume>91</volume>
<fpage>627</fpage>
<lpage>30</lpage>
</nlm-citation>
</ref>
<ref id="R18">
<label>18.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosca</surname><given-names>JD</given-names></name>
<name><surname>Pitha</surname><given-names>PM</given-names></name>
</person-group>
<article-title>Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis</article-title>
<source>Mol Cell Biol</source>
<year>1986</year>
<volume>6</volume>
<fpage>2279</fpage>
<lpage>83</lpage>
</nlm-citation>
</ref>
<ref id="R19">
<label>19.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fouchier</surname><given-names>RA</given-names></name>
<name><surname>Kuiken</surname><given-names>T</given-names></name>
<name><surname>Schutten</surname><given-names>M</given-names></name>
<etal></etal>
</person-group>
<article-title>Aetiology: Koch's postulates fulfilled for SARS virus</article-title>
<source>Nature</source>
<year>2003</year>
<volume>423</volume>
<fpage>240</fpage>
</nlm-citation>
</ref>
</ref-list>
<sec sec-type="display-object">
<title>Figures and Tables</title>
<fig id="F1" position="float">
<label>Figure 1.</label>
<caption>
<p>Cytopathic effect in severe acute respiratory syndrome-related coronavirus (SARS CoV)-infected Vero E6 cells. Vero E6 cells were infected with the SARS CoV at an MOI of 0.001 for 1 h and then were incubated in Dulbecco's modified Eagle's medium containing the indicated amounts of interferon-α-2b (IU/mL). Cells were fixed with 4% formalin on day 3 after infection.</p>
</caption>
<graphic mimetype="image" xlink:href="189-7-1164-fig001.tif"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of interferon (IFN)-α-2b on virus growth. <italic>A</italic>, Reduction of virus yield in the presence of antiviral activity. Vero E6 cells were infected with ∼100 pfu of the severe acute respiratory syndrome-related coronavirus (SARS CoV). At 1 h after infection, the supernatants were replaced with Dulbecco's modified Eagle's medium (DMEM) or DMEM containing the indicated amounts of IFN-α-2b (IU/mL) for a total of 72 h. Growth of the SARS CoV isolate Tor2 was determined by plaquetitration assay from 3 independent experiments, and data are mean ± SD. <italic>B</italic>, Analysis of cell-to-cell spread of SARS CoV in the presence and absence of IFN-α-2b. Vero E6 cell monolayers were infected with 10-fold dilutions of the SARS CoV. After 1 h of virus adsorption, the inoculum was removed, and cell monolayers were overlaid with 0.9% low-meltingpoint agarose in DMEM (B2) or DMEM containing 5000 IU/mL of IFNa- 2b (B1). On day 3 after infection, cells were stained with crystal violet. <italic>C</italic>, Protein analysis. Cell lysates were subjected to 10% SDS-PAGE. Protein was electrotransferred to polyvinylidene difluoride membrane (Immobilon P membrane; Millipore). Viral antigen was detected by use of a patient serum sample and horseradish peroxidase-conjugated anti-human IgG, by use of enhanced chemiluminescence. NP, nucleoprotein. <italic>D</italic>, Comparison of the effect of antiviral activity on different SARS CoV isolates. Vero E6 cells were infected with 4 independently isolated SARS CoVs (isolates Tor2, Tor3, Tor7, and Tor684) and were analyzed for their sensitivity to IFN-α-2b, as described above.</p>
</caption>
<graphic mimetype="image" xlink:href="189-7-1164-fig002.tif"></graphic>
</fig>
</sec>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial support: Health Canada severe acute respiratory syndrome-related fund.</p>
</fn>
</fn-group>
</back>
</article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α</title></titleInfo><name type="personal"><namePart type="given">Ute</namePart><namePart type="family">Ströher</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antonino</namePart><namePart type="family">DiCaro</namePart><affiliation>Laboratorio di Virologia-Padiglione Baglivi, Istituto Nazionale per le Malattie Infettive “L. Spallanzani”-IRCCS, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yan</namePart><namePart type="family">Li</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James E.</namePart><namePart type="family">Strong</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fred</namePart><namePart type="family">Aoki</namePart><affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frank</namePart><namePart type="family">Plummer</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steven M.</namePart><namePart type="family">Jones</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><affiliation>Department of Immunology, University of Manitoba, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Heinz</namePart><namePart type="family">Feldmann</namePart><affiliation>National Microbiology Laboratory, Health Canada, Winnipeg, Canada</affiliation><affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada</affiliation><affiliation>E-mail: heinz_feldmann@hc-sc.gc.ca</affiliation><affiliation>Reprints or correspondence: Dr. Heinz Feldmann, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2 (heinz_feldmann@hc-sc.gc.ca).</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="brief-report" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">2004-04-01</dateIssued><dateCreated encoding="w3cdtf">2003-10-03</dateCreated><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><abstract>Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.</abstract><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1164</start><end>1167</end></extent></part></relatedItem><relatedItem type="references" displayLabel="R1"><titleInfo><title>The genome sequence of the SARS-associated coronavirus</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Marra</namePart></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Jones</namePart></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Astell</namePart></name><genre>journal</genre><note>MarraMA JonesSJ AstellCR The genome sequence of the SARS-associated coronavirus Science 2003 300 1399 404</note><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1399</start><end>404</end><list>1399-404</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R2"><titleInfo><title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Rota</namePart></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Oberste</namePart></name><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Monroe</namePart></name><genre>journal</genre><note>RotaPA ObersteMS MonroeSS Characterization of a novel coronavirus associated with severe acute respiratory syndrome Science 2003 300 1394 9</note><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1394</start><end>9</end><list>1394-9</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R3"><titleInfo><title>A major outbreak of severe acute respiratory syndrome in Hong Kong</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Lee</namePart></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Hui</namePart></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Wu</namePart></name><genre>journal</genre><note>LeeN HuiD WuA A major outbreak of severe acute respiratory syndrome in Hong Kong N Engl J Med 2003 348 1986 94</note><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1986</start><end>94</end><list>1986-94</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R4"><titleInfo><title>Identification of severe acute respiratory syndrome in Canada</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Poutanen</namePart></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Low</namePart></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Henry</namePart></name><genre>journal</genre><note>PoutanenSM LowDE HenryB Identification of severe acute respiratory syndrome in Canada N Engl J Med 2003 348 1995 2005</note><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1995</start><end>2005</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R5"><titleInfo><title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</title></titleInfo><name type="personal"><namePart type="given">KW</namePart><namePart type="family">Tsang</namePart></name><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Ho</namePart></name><name type="personal"><namePart type="given">GC</namePart><namePart type="family">Ooi</namePart></name><genre>journal</genre><note>TsangKW HoPL OoiGC A cluster of cases of severe acute respiratory syndrome in Hong Kong N Engl J Med 2003 348 1977 85</note><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1977</start><end>85</end><list>1977-85</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R6"><titleInfo><title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cinatl</namePart></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Morgenstern</namePart></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Bauer</namePart></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Chandra</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Rabenau</namePart></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Doerr</namePart></name><genre>journal</genre><note>CinatlJ MorgensternB BauerG ChandraP RabenauH DoerrHW Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus Lancet 2003 361 2045 6</note><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>2045</start><end>6</end><list>2045-6</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R7"><titleInfo><title>Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro</title></titleInfo><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Weiss</namePart></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Oostrom-Ram</namePart></name><genre>journal</genre><note>WeissRC Oostrom-RamT Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro Vet Microbiol 1989 20 255 65</note><relatedItem type="host"><titleInfo><title>Vet Microbiol</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>255</start><end>65</end><list>255-65</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R8"><titleInfo><title>Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug</title></titleInfo><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Huggins</namePart></name><genre>journal</genre><note>HugginsJW Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug Rev Infect Dis 1989 11 (Suppl 4) S750 61</note><relatedItem type="host"><titleInfo><title>Rev Infect Dis</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>(Suppl 4)</number></detail><extent unit="pages"><start>S750</start><end>61</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R9"><titleInfo><title>Effect of ribavirin on bunyavirus reproduction in cell culture and in an experiment on white mice</title></titleInfo><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Berezina</namePart></name><name type="personal"><namePart type="given">NA</namePart><namePart type="family">Leont'eva</namePart></name><name type="personal"><namePart type="given">NG</namePart><namePart type="family">Kondrashina</namePart></name><name type="personal"><namePart type="given">DK</namePart><namePart type="family">L'Vov</namePart></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Gagelov</namePart></name><genre>journal</genre><note>[in Russian]</note><note>BerezinaLK Leont'evaNA KondrashinaNG L'VovDK GagelovGA Effect of ribavirin on bunyavirus reproduction in cell culture and in an experiment on white mice Vopr Virusol 1983 28 627 9 [in Russian]</note><relatedItem type="host"><titleInfo><title>Vopr Virusol</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>627</start><end>9</end><list>627-9</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R10"><titleInfo><title>Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Andrei</namePart></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">De Clercq</namePart></name><genre>journal</genre><note>AndreiG De ClercqE Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro Antiviral Res 1990 14 287 99</note><relatedItem type="host"><titleInfo><title>Antiviral Res</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>287</start><end>99</end><list>287-99</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R11"><titleInfo><title>The biological relationship of mouse hepatitis virus (MHV) strains and interferon: in vitro induction and sensitivities</title></titleInfo><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Garlinghouse Jr.</namePart></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Smith</namePart></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Holford</namePart></name><genre>journal</genre><note>GarlinghouseLEJr. SmithAL HolfordT The biological relationship of mouse hepatitis virus (MHV) strains and interferon: in vitro induction and sensitivities Arch Virol 1984 82 19 29</note><relatedItem type="host"><titleInfo><title>Arch Virol</title></titleInfo><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>19</start><end>29</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R12"><titleInfo><title>Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta</title></titleInfo><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Sperber</namePart></name><name type="personal"><namePart type="given">FG</namePart><namePart type="family">Hayden</namePart></name><genre>journal</genre><note>SperberSJ HaydenFG Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta J Interferon Res 1989 9 285 93</note><relatedItem type="host"><titleInfo><title>J Interferon Res</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>285</start><end>93</end><list>285-93</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R13"><titleInfo><title>Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mochizuki</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Nakatani</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Yoshida</namePart></name><genre>journal</genre><note>MochizukiM NakataniH YoshidaM Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro Vet Microbiol 1994 39 145 52</note><relatedItem type="host"><titleInfo><title>Vet Microbiol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>145</start><end>52</end><list>145-52</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R14"><titleInfo><title>Antiviral action of interferon-alpha against porcine transmissible gastroenteritis virus</title></titleInfo><name type="personal"><namePart type="given">LT</namePart><namePart type="family">Jordan</namePart></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Derbyshire</namePart></name><genre>journal</genre><note>JordanLT DerbyshireJB Antiviral action of interferon-alpha against porcine transmissible gastroenteritis virus Vet Microbiol 1995 45 59 70</note><relatedItem type="host"><titleInfo><title>Vet Microbiol</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>59</start><end>70</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R15"><titleInfo><title>Mass spectrometric characterization of proteins from the SARS virus: a preliminary report</title></titleInfo><name type="personal"><namePart type="given">O</namePart><namePart type="family">Krokhin</namePart></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Li</namePart></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Andonov</namePart></name><genre>journal</genre><note>KrokhinO LiY AndonovA Mass spectrometric characterization of proteins from the SARS virus: a preliminary report Mol Cell Proteomics 2003 2 346 56</note><relatedItem type="host"><titleInfo><title>Mol Cell Proteomics</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>346</start><end>56</end><list>346-56</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R16"><titleInfo><title>Clinical pharmacokinetics of interferons</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Wills</namePart></name><genre>journal</genre><note>WillsRJ Clinical pharmacokinetics of interferons Clin Pharmacokinet 1990 19 390 9</note><relatedItem type="host"><titleInfo><title>Clin Pharmacokinet</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>390</start><end>9</end><list>390-9</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R17"><titleInfo><title>Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Hausfater</namePart></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Cacoub</namePart></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Assogba</namePart></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Lebon</namePart></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Piette</namePart></name><genre>journal</genre><note>HausfaterP CacoubP AssogbaU LebonP PietteJC Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis Nephron 2002 91 627 30</note><relatedItem type="host"><titleInfo><title>Nephron</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>627</start><end>30</end><list>627-30</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R18"><titleInfo><title>Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis</title></titleInfo><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Mosca</namePart></name><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Pitha</namePart></name><genre>journal</genre><note>MoscaJD PithaPM Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis Mol Cell Biol 1986 6 2279 83</note><relatedItem type="host"><titleInfo><title>Mol Cell Biol</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>2279</start><end>83</end><list>2279-83</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R19"><titleInfo><title>Aetiology: Koch's postulates fulfilled for SARS virus</title></titleInfo><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Fouchier</namePart></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kuiken</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schutten</namePart></name><genre>journal</genre><note>FouchierRA KuikenT SchuttenM Aetiology: Koch's postulates fulfilled for SARS virus Nature 2003 423 240</note><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>423</number></detail><extent unit="pages"><start>240</start></extent></part></relatedItem></relatedItem><identifier type="istex">FF63A99965ECDC1E7144CBE4D3273B2F908720A3</identifier><identifier type="ark">ark:/67375/HXZ-KP6RTLL1-8</identifier><identifier type="DOI">10.1086/382597</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2004 by the Infectious Diseases Society of America</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.10) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2020-04-17</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/record.json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/FF63A99965ECDC1E7144CBE4D3273B2F908720A3/covers/tiff</uri></json:item></covers><annexes><json:item><extension>gif</extension><original>true</original><mimetype>image/gif</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/annexes.gif</uri></json:item><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-KP6RTLL1-8/annexes.jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000080 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000080 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FF63A99965ECDC1E7144CBE4D3273B2F908720A3
|texte= Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α
}}
| This area was generated with Dilib version V0.6.33. |  |